Giles FJ - Search Results

1

MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, Zhao B, Bergstrom D, Le Coutre PD, Freedman SJ, Cortes JE. Giles FJ, et al. Leukemia. 2013 Jan;27(1):113-7. doi: 10.1038/leu.2012.186. Epub 2012 Jul 9. Leukemia. 2013. PMID: 22772060 Clinical Trial.

2

The treatment of myelofibrosis with alfa-interferon.

McCarthy D, Clark J, Giles F. McCarthy D, et al. Br J Haematol. 1991 Aug;78(4):590-1. doi: 10.1111/j.1365-2141.1991.tb04508.x. Br J Haematol. 1991. PMID: 1911363 No abstract available.

3

Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia.

Kattan MW, Inoue Y, Giles FJ, Talpaz M, Ozer H, Guilhot F, Zuffa E, Huber SL, Beck JR. Kattan MW, et al. Among authors: giles fj. Ann Intern Med. 1996 Oct 1;125(7):541-8. doi: 10.7326/0003-4819-125-7-199610010-00002. Ann Intern Med. 1996. PMID: 8815752

4

Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy.

Kantarjian HM, Giles FJ, O'Brien SM, Talpaz M. Kantarjian HM, et al. Among authors: giles fj. Hematol Oncol Clin North Am. 1998 Feb;12(1):31-80. doi: 10.1016/s0889-8588(05)70496-2. Hematol Oncol Clin North Am. 1998. PMID: 9523225 Review.

5

Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.

Kantarjian HM, O'Brien S, Smith TL, Rios MB, Cortes J, Beran M, Koller C, Giles FJ, Andreeff M, Kornblau S, Giralt S, Keating MJ, Talpaz M. Kantarjian HM, et al. Among authors: giles fj. J Clin Oncol. 1999 Jan;17(1):284-92. doi: 10.1200/JCO.1999.17.1.284. J Clin Oncol. 1999. PMID: 10458244 Clinical Trial.

6

Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance.

Giles FJ, Kantarjian HM, Cortes J, Thomas DA, Talpaz M, Manshouri T, Albitar M. Giles FJ, et al. Cancer. 1999 Sep 1;86(5):805-13. Cancer. 1999. PMID: 10463979

7

Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.

Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, O'Brien S, Giles FJ, Gajewski J, Pierce S, Keating MJ. Thomas DA, et al. Among authors: giles fj. Cancer. 1999 Oct 1;86(7):1216-30. doi: 10.1002/(sici)1097-0142(19991001)86:7<1216::aid-cncr17>3.0.co;2-o. Cancer. 1999. PMID: 10506707 Clinical Trial.

8

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.

Beran M, Estey E, O'Brien S, Cortes J, Koller CA, Giles FJ, Kornblau S, Andreeff M, Vey N, Pierce SR, Hayes K, Wong GC, Keating M, Kantarjian H. Beran M, et al. Among authors: giles fj. J Clin Oncol. 1999 Sep;17(9):2819-30. doi: 10.1200/JCO.1999.17.9.2819. J Clin Oncol. 1999. PMID: 10561358 Clinical Trial.

9

A pilot study of recombinant human interleukin-4 therapy of myelofibrosis.

Giles FJ, Keating AR, Kurzrock R, Talpaz M. Giles FJ, et al. J Interferon Cytokine Res. 1999 Nov;19(11):1253-5. doi: 10.1089/107999099312911. J Interferon Cytokine Res. 1999. PMID: 10574617 Clinical Trial.

10

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

Sacchi S, Kantarjian HM, O'Brien S, Cortes J, Rios MB, Giles FJ, Beran M, Koller CA, Keating MJ, Talpaz M. Sacchi S, et al. Among authors: giles fj. Cancer. 1999 Dec 15;86(12):2632-41. doi: 10.1002/(sici)1097-0142(19991215)86:12<2632::aid-cncr7>3.0.co;2-a. Cancer. 1999. PMID: 10594858

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

652 results

Search Page